Sucralfate NDC 17856-0306

NDC codes

FDA NDC Directory

Product NDC (as listed)17856-0306Labeler and product segments. Claims need a package NDC.

Product NDC at billing width17856-0306Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
17856-0306-1	17856030601	72 CUP, UNIT-DOSE in 1 BOX, UNIT-DOSE (17856-0306-1) / 10 mL in 1 CUP, UNIT-DOSEMarketed from Aug 10, 2023

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Sucralfate
Generic name (nonproprietary): sucralfate
Active ingredients: Sucralfate — 1 g/10mL
Dosage form: Suspension
Route: Oral
Labeler: ATLANTIC BIOLOGICALS CORP.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 211884
Marketing start: Mar 15, 2022
Listing expires: Dec 31, 2026
Other FDA classes: Organometallic Compounds (Chemical structure)
Identifiers: Product ID 17856-0306_361f83ba-0caa-c1c1-e063-6394a90a4c10SPL ID 361f83ba-0caa-c1c1-e063-6394a90a4c10SPL set ID e5073597-ac51-4e7c-a9dc-7695773a01f1RxCUI 313123UNII XX73205DH5
Pharmacologic class: Aluminum Complex

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N417856030601 followed by a unit qualifier and the quantity

Package 17856-0306-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 27, 2025.

Indications (excerpt from the label)

INDICATIONS AND USAGE Sucralfate Oral Suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 211884

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 211884
Product	Strength	Form · route	Labeler	Product NDC
Sucralfate	Sucralfate 1 g/10mL	SuspensionOral	PAI Holdings, LLC dba PAI Pharma	0121-0974
Sucralfatesucralfate oral suspension	Sucralfate 1 g/10mL	SuspensionOral	Major Pharmaceuticals	0904-7470
Sucralfate	Sucralfate 1 g/10mL	SuspensionOral	American Health Packaging	60687-738
Sucralfate	Sucralfate 1 g/10mL	SuspensionOral	Cardinal Health 107, LLC	55154-5790
Sucralfate	Sucralfate 1 g/10mL	SuspensionOral	VistaPharm, LLC	66689-305